Microbio’s botanical new drug (Chemo Young) received patent from State Intellectual Property Office of the P.R.C on “USE OF A FERMENTED SOY EXTRACT FOR MANUFACTURE OF A PREBIOTIC COMPOSITION” on April 15, 2015.

This invention encompasses the application of Chemo Young in protecting intestinal probiotics from the damages caused by the use of antibiotics. Recent reports from Nature and Science journals have reported that the use of antibiotics in chemotherapy treated cancer patients can lead to eradication of intestinal microbiome and lead to immune dysfunction, and cause reduced he efficacy of chemotherapy agent such as cyclophosphamide.

Chemo Young promotes the proliferation of probiotic microbiological populations of the gut and reduces the adverse effect from antibiotic. Human clinical trial has shown that consumption of Chemo Young can help maintaining the number of peripheral blood mononuclear cells (PBMCs) and preserve immunity in cancer patients. Chemo Young is a novel drug approved in Taiwan and has proven to be effective as a cancer adjuvant therapy.